Stock ALLO ALLOGENE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Allogene Therapeutics, Inc.

Equities

ALLO

US0197701065

Biotechnology & Medical Research

Real-time Estimate Cboe BZX
Other stock markets
 11:27:19 2024-04-26 am EDT 		5-day change 1st Jan Change
2.815 USD -1.40% Intraday chart for Allogene Therapeutics, Inc. -19.31% -12.77%
04:40pm Allogene Therapeutics Gets $15 Million Grant from California Institute for Regenerative Medicine for Cancer Drug Development MT
Mar. 18 Allogene Therapeutics, Inc.(NasdaqGS:ALLO) added to S&P Biotechnology Select Industry Index CI

Business Summary

Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on four core programs: Large B-Cell Lymphoma (LBCL), Chronic Lymphocytic Leukemia (CLL), Autoimmune Disease and Renal Cell Carcinoma. It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL and CLL. Its pipeline also includes ALLO-316, ALLO-329 and ALLO-647.

Number of employees: 233

Sales per Business

USD in Million2022Weight2023Weight Delta
Allogeneic T Cell Therapies
100.0 %
0 100.0 % 0 100.0 % -60.91%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
0 100.0 % 0 100.0 % -60.91%

Managers

Managers TitleAgeSince
Joshua Kazam FOU
 Founder 47 17-10-31
David Chang FOU
 Founder 64 18-03-31
Geoffrey Parker DFI
 Director of Finance/CFO 59 23-10-15
Lillian Smith CMP
 Compliance Officer 52 23-03-31
Zachary Roberts CTO
 Chief Tech/Sci/R&D Officer 46 23-01-02
Timothy Moore CTO
 Chief Tech/Sci/R&D Officer 62 23-03-31
Earl Douglas CMP
 Compliance Officer 61 23-08-13
Jack Chen AUD
 Comptroller/Controller/Auditor - -
Susan R. Lundeen-Smuck HRO
 Human Resources Officer 58 22-05-01
Christine Cassiano LAW
 General Counsel - 18-02-28

Members of the board

Members of the board TitleAgeSince
David Bonderman BRD
 Director/Board Member 81 18-04-30
Joshua Kazam FOU
 Founder 47 17-10-31
Arie Belldegrun FOU
 Founder 74 17-10-31
Vicki Sato BRD
 Director/Board Member 75 21-07-29
Todd Sisitsky BRD
 Director/Board Member 52 18-03-31
Stephen Mayo BRD
 Director/Board Member 62 22-07-11
Elizabeth Barrett BRD
 Director/Board Member 62 21-07-29
Deborah Messemer BRD
 Director/Board Member 66 18-09-27
Owen N. Witte BRD
 Director/Board Member 74 18-03-31
David Chang FOU
 Founder 64 18-03-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 170,723,100 114,060,807 ( 66.81 %) 0 66.81 %

Shareholders

NameEquities%Valuation
Fidelity Management & Research Co. LLC
14.93 %
25,241,499 14.93 % 113 M $
PFIZER, INC.
13.03 %
22,032,040 13.03 % 98 M $
TPG Group Holdings (SBS) Advisors, Inc.
11.07 %
18,716,306 11.07 % 84 M $
BlackRock Advisors LLC
5.467 %
9,243,817 5.467 % 41 M $
Vanguard Fiduciary Trust Co.
5.341 %
9,030,825 5.341 % 40 M $
David Chang
4.364 %
7,378,474 4.364 % 33 M $
JPMorgan Investment Management, Inc.
4.085 %
6,906,761 4.085 % 31 M $
Arie Belldegrun
3.890 %
6,576,979 3.890 % 29 M $
PRIMECAP Management Co.
3.124 %
5,281,886 3.124 % 24 M $
Citadel Securities GP LLC
2.397 %
4,053,226 2.397 % 18 M $

Company contact information

Allogene Therapeutics, Inc.

210 East Grand Avenue

94080-4811, South San Francisco

+

http://www.allogene.com
address Allogene Therapeutics, Inc.(ALLO)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Ratings for Allogene Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
2.855 USD
Average target price
11.66 USD
Spread / Average Target
+308.35%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ALLOGENE THERAPEUTICS, INC. Stock Allogene Therapeutics, Inc.
-10.59% 487M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.29% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.96% 95.71B
ARGENX SE Stock argenx SE
+1.89% 22.02B
BIONTECH SE Stock BioNTech SE
-16.43% 20.9B
GENMAB A/S Stock Genmab A/S
-9.05% 17.85B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.83% 16.21B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.89% 15.52B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.56% 13.86B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.36% 12.04B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ALLO Stock
  4. Company Allogene Therapeutics, Inc.